Pharmaceutical R D Costs Risks And Rewards
DOWNLOAD
FREE 30 Days
Download Pharmaceutical R D Costs Risks And Rewards PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Pharmaceutical R D Costs Risks And Rewards book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages. If the content not found or just blank you must refresh this page
Pharmaceutical R D Costs Risks And Rewards
DOWNLOAD
FREE 30 Days
Author :
language : en
Publisher: DIANE Publishing
Release Date : 1993
Pharmaceutical R D Costs Risks And Rewards written by and has been published by DIANE Publishing this book supported file pdf, txt, epub, kindle and other format this book has been release on 1993 with categories.
Pharmaceutical R D
DOWNLOAD
FREE 30 Days
Author :
language : en
Publisher: DIANE Publishing
Release Date : 1993
Pharmaceutical R D written by and has been published by DIANE Publishing this book supported file pdf, txt, epub, kindle and other format this book has been release on 1993 with Drugs categories.
Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.
Pharmaceutical R And D
DOWNLOAD
FREE 30 Days
Author : Office of Technology Assessment
language : en
Publisher:
Release Date : 2005
Pharmaceutical R And D written by Office of Technology Assessment and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 2005 with Medical categories.
Pharmaceutical costs are among the fastest growing components of health care costs today. Although increases in the inflation-adjusted prices of ethical drugs and perceived high prices of new drugs have been a concern of congressional committees for over 30 years, the growing Federal role in paying for prescription drugs has increased the concern over the appropriateness of prices relative to the costs of bringing new drugs to market. Specific policies of U.S. and other governments can alter the delicate balance between costs and returns to pharmaceutical R&D, with ramifications for the future health of Americans, for health care costs, and for the future of the U.S. pharmaceutical industry. OTA's report focuses mainly on the economic side of the R&D process. Pharmaceutical R&D is an investment, and the principal characteristic of an investment is that money is spent today in the hopes of generating even more money in the future. Pharmaceutical R&D is a risky investment; therefore, high financial returns are necessary to induce companies to invest in researching new chemical entities. Changes in Federal policy that affect the cost, uncertainty and returns of pharmaceutical R&D may have dramatic effects on the investment patterns of the industry. Given this sensitivity to policy changes, careful consideration of the effects on R&D is needed. The specific request for this study came from the House Committee on Energy and Commerce and its Subcommittee on Health and the Environment. The Senate Committee on the Judiciary's Subcommittee on Antitrust, Monopolies, and Business Rights endorsed the study. OTA was assisted in this study by an advisory panel of business, consumer, and academicleaders chaired by Frederick M. Scherer, Ph.D., Professor of Economics, John E Kennedy School of Government at Harvard University. OTA gratefully acknowledges the contribution of each of these individuals. As with all OTA reports, the final responsibility for the content of the assessment rests with OTA.
Pharmaceutical R D
DOWNLOAD
FREE 30 Days
Author :
language : en
Publisher: U.S. Government Printing Office
Release Date : 1993
Pharmaceutical R D written by and has been published by U.S. Government Printing Office this book supported file pdf, txt, epub, kindle and other format this book has been release on 1993 with Drugs categories.
Research and development expenditures -- The costs of pharmaceuticul r & d -- Returns on pharmaceutical r & d -- Trends in science, technology and drug discovery -- Government regulation and pharmaceutical r & d -- Product liability and the pharmaceutical industry -- Federal tax policy and drug research and development -- Federal support for pharmaceutical research and development -- Trends in payment for prescription drugs.
Risk Sharing In The Pharmaceutical Industry
DOWNLOAD
FREE 30 Days
Author : Gerrit Reepmeyer
language : en
Publisher: Springer Science & Business Media
Release Date : 2005-12-05
Risk Sharing In The Pharmaceutical Industry written by Gerrit Reepmeyer and has been published by Springer Science & Business Media this book supported file pdf, txt, epub, kindle and other format this book has been release on 2005-12-05 with Business & Economics categories.
The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.
Research And Development In The Pharmaceutical Industry A Cbo Study
DOWNLOAD
FREE 30 Days
Author : Congressional Budget Office
language : en
Publisher: Lulu.com
Release Date : 2013-06-09
Research And Development In The Pharmaceutical Industry A Cbo Study written by Congressional Budget Office and has been published by Lulu.com this book supported file pdf, txt, epub, kindle and other format this book has been release on 2013-06-09 with Science categories.
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Competitive Strategies In The Pharmaceutical Industry
DOWNLOAD
FREE 30 Days
Author : Robert B. Helms
language : en
Publisher: A E I Press
Release Date : 1996
Competitive Strategies In The Pharmaceutical Industry written by Robert B. Helms and has been published by A E I Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 1996 with Business & Economics categories.
The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products - even though new technologies have increased both the cost and the medical attractiveness of those products. Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research. This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.
Powerful Medicines
DOWNLOAD
FREE 30 Days
Author : Jerry Avorn
language : en
Publisher: Vintage
Release Date : 2005
Powerful Medicines written by Jerry Avorn and has been published by Vintage this book supported file pdf, txt, epub, kindle and other format this book has been release on 2005 with Health & Fitness categories.
A provocative investigation into the approval, pricing, marketing, and misuse of prescription drugs details the often contentious relationships between pharmaceutical companies, the FDA, and doctors, citing the detriments of drug promotions while arguing for a national agenda to promote improved drug pricing and application. Reprint. 10,000 first printing.
Benefit Risk Assessment In Pharmaceutical Research And Development
DOWNLOAD
FREE 30 Days
Author : Andreas Sashegyi
language : en
Publisher: CRC Press
Release Date : 2013-11-27
Benefit Risk Assessment In Pharmaceutical Research And Development written by Andreas Sashegyi and has been published by CRC Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 2013-11-27 with Mathematics categories.
Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations rele
Drug Benefits And Risks
DOWNLOAD
FREE 30 Days
Author : Chris J. van Boxtel
language : en
Publisher: John Wiley & Sons
Release Date : 2001-11-28
Drug Benefits And Risks written by Chris J. van Boxtel and has been published by John Wiley & Sons this book supported file pdf, txt, epub, kindle and other format this book has been release on 2001-11-28 with Medical categories.
This is an inclusive reference exploring the scientific basis and practice of drug therapy. The key concept is to look at the balance between the benefits and risks of drugs but in this context also the social impact which drugs have in modern societies is highlighted. Taking an evidence-based approach to the problem, the practice of clinical pharmacology and pharmacotherapy in the developing as well as the developed world is examined. For this purpose the book * Covers general clinical pharmacology, pharmacology of various drug groups and the treatments specific to various diseases * Gives guidance on how doctors should act so that drugs can be used effectively and safely * Encourages the rational use of drugs in society This book brings together a large amount of excellent content that will be invaluable for anyone working within, or associated with, the field of clinical pharmacology and pharmacotherapy - undergraduates, postgraduates, regulatory authorities and the pharmaceutical industry.